Cue Biopharma Stock Probability Of Bankruptcy

CUE Stock

USD 1.01 0.01 0.98%

Cue Biopharma's chance of distress is over 60% at the present time. It has an above-average odds of going through some form of financial crisis in the next 2 years. Cue Biopharma's Probability of distress is determined by interpolating and adjusting Cue Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the Cue balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Cue Biopharma Piotroski F Score and Cue Biopharma Altman Z Score analysis.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

The current year's Market Cap is expected to grow to about 240.6 M, whereas Enterprise Value is forecasted to decline to about 82.6 M.

Cue Biopharma Company probability of distress Analysis

Cue Biopharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Cue Biopharma Probability Of Bankruptcy

Over 69%

Most of Cue Biopharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cue Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Cue Biopharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Cue Biopharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Cue Biopharma financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.91)

Revenue Per Share

0.172

Quarterly Revenue Growth

0.923

Return On Assets

(0.52)

Return On Equity

(1.39)

The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Deferred Long Term Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Intangible Assets	Capital Surpluse	Capital Stock	Long Term Debt	Long Term Debt Total
Total Assets		0.99	0.97	-0.91	-0.78	0.83	0.54	0.91	0.82	1.0	0.88	0.53	0.69	0.33	0.15	-0.2	-0.09	0.81	-0.84	0.74	0.69	-0.23	-0.23
Total Stockholder Equity	0.99		0.94	-0.95	-0.7	0.76	0.49	0.83	0.82	0.99	0.8	0.52	0.66	0.33	0.2	-0.27	-0.01	0.76	-0.77	0.64	0.59	-0.15	-0.18
Net Tangible Assets	0.97	0.94		-0.91	-0.82	0.89	0.41	0.92	0.84	0.97	0.92	0.48	0.65	0.39	0.04	0.02	-0.2	0.81	-0.82	0.8	0.76	-0.4	-0.31
Net Debt	-0.91	-0.95	-0.91		0.57	-0.68	-0.25	-0.7	-0.79	-0.93	-0.69	-0.44	-0.61	-0.45	-0.2	0.17	-0.02	-0.74	0.62	-0.53	-0.46	0.15	0.15
Retained Earnings	-0.78	-0.7	-0.82	0.57		-0.9	-0.32	-0.91	-0.59	-0.75	-0.94	-0.33	-0.51	-0.4	0.01	-0.3	0.41	-0.81	0.86	-0.95	-0.96	0.71	0.66
Accounts Payable	0.83	0.76	0.89	-0.68	-0.9		0.41	0.92	0.79	0.81	0.96	0.27	0.46	0.42	-0.18	0.17	-0.42	0.8	-0.85	0.89	0.86	-0.54	-0.4
Short Term Investments	0.54	0.49	0.41	-0.25	-0.32	0.41		0.58	0.52	0.53	0.47	0.49	0.49	-0.41	-0.1	-0.55	-0.05	0.21	-0.6	0.29	0.3	0.22	0.21
Total Liab	0.91	0.83	0.92	-0.7	-0.91	0.92	0.58		0.73	0.88	0.98	0.5	0.67	0.3	-0.03	0.01	-0.29	0.82	-0.93	0.91	0.88	-0.45	-0.34
Deferred Long Term Liab	0.82	0.82	0.84	-0.79	-0.59	0.79	0.52	0.73		0.84	0.75	0.53	0.47	0.21	-0.34	-0.1	-0.43	0.55	-0.73	0.5	0.47	-0.24	-0.17
Total Current Assets	1.0	0.99	0.97	-0.93	-0.75	0.81	0.53	0.88	0.84		0.85	0.53	0.69	0.3	0.15	-0.21	-0.07	0.78	-0.81	0.7	0.65	-0.22	-0.23
Common Stock	0.88	0.8	0.92	-0.69	-0.94	0.96	0.47	0.98	0.75	0.85		0.41	0.55	0.32	-0.06	0.16	-0.34	0.77	-0.87	0.94	0.93	-0.54	-0.41
Property Plant Equipment	0.53	0.52	0.48	-0.44	-0.33	0.27	0.49	0.5	0.53	0.53	0.41		0.57	0.06	-0.3	-0.26	-0.37	0.31	-0.62	0.2	0.2	-0.08	-0.12
Current Deferred Revenue	0.69	0.66	0.65	-0.61	-0.51	0.46	0.49	0.67	0.47	0.69	0.55	0.57		0.06	0.13	-0.15	-0.03	0.64	-0.69	0.46	0.43	-0.22	-0.23
Net Receivables	0.33	0.33	0.39	-0.45	-0.4	0.42	-0.41	0.3	0.21	0.3	0.32	0.06	0.06		-0.02	0.14	-0.21	0.71	-0.36	0.4	0.29	-0.3	-0.26
Net Invested Capital	0.15	0.2	0.04	-0.2	0.01	-0.18	-0.1	-0.03	-0.34	0.15	-0.06	-0.3	0.13	-0.02		-0.27	0.87	0.11	0.2	0.08	0.05	0.29	0.12
Short Long Term Debt	-0.2	-0.27	0.02	0.17	-0.3	0.17	-0.55	0.01	-0.1	-0.21	0.16	-0.26	-0.15	0.14	-0.27		-0.48	-0.01	0.08	0.3	0.38	-0.85	-0.67
Net Working Capital	-0.09	-0.01	-0.2	-0.02	0.41	-0.42	-0.05	-0.29	-0.43	-0.07	-0.34	-0.37	-0.03	-0.21	0.87	-0.48		-0.18	0.45	-0.24	-0.3	0.66	0.56
Short Term Debt	0.81	0.76	0.81	-0.74	-0.81	0.8	0.21	0.82	0.55	0.78	0.77	0.31	0.64	0.71	0.11	-0.01	-0.18		-0.84	0.79	0.7	-0.41	-0.38
Intangible Assets	-0.84	-0.77	-0.82	0.62	0.86	-0.85	-0.6	-0.93	-0.73	-0.81	-0.87	-0.62	-0.69	-0.36	0.2	0.08	0.45	-0.84		-0.77	-0.75	0.42	0.4
Capital Surpluse	0.74	0.64	0.8	-0.53	-0.95	0.89	0.29	0.91	0.5	0.7	0.94	0.2	0.46	0.4	0.08	0.3	-0.24	0.79	-0.77		0.98	-0.62	-0.47
Capital Stock	0.69	0.59	0.76	-0.46	-0.96	0.86	0.3	0.88	0.47	0.65	0.93	0.2	0.43	0.29	0.05	0.38	-0.3	0.7	-0.75	0.98		-0.69	-0.56
Long Term Debt	-0.23	-0.15	-0.4	0.15	0.71	-0.54	0.22	-0.45	-0.24	-0.22	-0.54	-0.08	-0.22	-0.3	0.29	-0.85	0.66	-0.41	0.42	-0.62	-0.69		0.9
Long Term Debt Total	-0.23	-0.18	-0.31	0.15	0.66	-0.4	0.21	-0.34	-0.17	-0.23	-0.41	-0.12	-0.23	-0.26	0.12	-0.67	0.56	-0.38	0.4	-0.47	-0.56	0.9

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	(0.51)	(0.45)	(0.53)	(0.58)	(0.82)	(0.87)
Asset Turnover	0.0483	0.0317	0.18	0.0136	0.0892	0.0516
Gross Profit Margin	(6.95)	(9.63)	1.12	(0.45)	(5.94)	(6.24)
Net Debt	(38.5M)	(67.7M)	(54.3M)	(32.3M)	(33.8M)	(35.5M)
Total Current Liabilities	11.7M	16.3M	12.8M	11.5M	17.1M	10.1M
Non Current Liabilities Total	5.4M	4.3M	5.1M	14.1M	7.4M	5.1M
Total Assets	71.6M	99.5M	83.4M	91.3M	61.5M	66.4M
Total Current Assets	61.0M	87.5M	68.5M	77.2M	51.5M	57.8M
Total Cash From Operating Activities	(30.8M)	(32.5M)	(38.8M)	(41.8M)	(40.0M)	(42.0M)

	Return On Equity	-1.39
	Return On Asset	-0.52
	Operating Margin	(3.91) %
	Current Valuation	44.88 M
	Shares Outstanding	63.35 M
	Shares Owned By Insiders	0.54 %
	Shares Owned By Institutions	23.59 %
	Number Of Shares Shorted	1 M
	Price To Earning	(2.17) X
	Price To Book	2.67 X
	Price To Sales	7.79 X
	Revenue	5.49 M
	Gross Profit	1.25 M
	EBITDA	(46.05 M)
	Net Income	(50.73 M)
	Cash And Equivalents	66.13 M
	Cash Per Share	1.87 X
	Total Debt	14.7 M
	Debt To Equity	0.33 %
	Current Ratio	8.29 X
	Book Value Per Share	0.79 X
	Cash Flow From Operations	(39.96 M)
	Short Ratio	1.54 X
	Earnings Per Share	(0.91) X
	Target Price	3.6
	Number Of Employees	53
	Beta	1.8
	Market Capitalization	64.62 M
	Total Asset	61.53 M
	Retained Earnings	(301.19 M)
	Working Capital	34.37 M
	Current Asset	42.21 M
	Current Liabilities	3.38 M
	Net Asset	61.53 M

Cue Biopharma Stock Probability Of Bankruptcy

Cue Biopharma Company probability of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Cue Biopharma Probability Of Bankruptcy

Cue Probability Of Bankruptcy Driver Correlations

Cue Probability Of Bankruptcy Peer Comparison

Cue Biopharma Main Bankruptcy Drivers

Cue Fundamentals

About Cue Biopharma Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY